Hypothyroidism Overtreatment Linked to Risk of ... - Thyroid UK

Thyroid UK

141,240 members166,488 posts

Hypothyroidism Overtreatment Linked to Risk of Atrial Fibrillation

Timsywhimsy profile image
13 Replies

Hi all, I’ve copied this from medscape as its log-in only and I can’t find the actual study.....anyway, curious to hear what everyone thinks. I know many on here say low tsh is just fine, but this seems to say otherwise. It doesn’t look like they measured frees but I still think this study is worth thinking about because it’s actually looking at tsh in treated hypos, NOT in those with ‘true’ hyperthyroidism.

CHICAGO — Low levels of thyroid stimulating hormone (TSH) that result from the over-treatment of hypothyroidism are associated with a significantly increased risk of atrial fibrillation and stroke, according to results from a large, population-based study using data from the Veterans Health Administration.

"Our study provides new insights on the incidence of atrial fibrillation and stroke in patients being treated with exogenous thyroid hormone," lead author Maria Papaleontiou, MD, told Medscape Medical News.

"We found that despite controlling for known cardiovascular risk factors, such as smoking, hypertension, etc, lower serum TSH was associated with both incident atrial fibrillation and stroke," she said.

Papaleontiou, who is an assistant professor of internal medicine, Division of Metabolism, Endocrinology, and Diabetes at the University of Michigan, Ann Arbor, presented the findings at the 89th American Thyroid Association (ATA) Annual Meeting.

The study received funding from the National Institute on Aging and the Michigan Biology of Cardiovascular Aging program.

Endogenous hyperthyroidism has been shown to be associated with cardiovascular risks, however, the effects of exogenous hyperthyroidism, defined as lower TSH levels caused by exogenous factors — specifically medical over-treatment of hypothyroidism — have not been well established.

Levothyroxine for hypothyroidism is the most commonly prescribed medication in the United States, and as over-replacement is known to be very common, the issue is important.

Asked to comment, Mona M. Sabra, MD, said these latest findings underscore the need to avoid hypothyroidism over-treatment, when possible.

"The cardiovascular risk with suppressed TSH levels can be seen with (hypothyroidism) overtreatment as well as hyperthyroidism from Graves disease or other causes of suppressed TSH, and it is also associated with a risk of death," she told Medscape Medical News.

"Therefore, these data suggest that suppressed TSH levels should be treated and avoided when possible," said Sabra, who is a professor of clinical medicine, Endocrine Service, Department of Medicine, Memorial Sloan Kettering and Weill Cornell School of Medicine, New York City.

However, she acknowledged, "In thyroid cancer patients who are at high risk for recurrence, this may not be possible because the risk of cancer may outweigh the risk of suppressed TSH."

Almost a Third of Patients With Hypothyroidism Were Overtreated

For the study, Papaleontiou and colleagues identified 643,054 patients in the Corporate Data Warehouse of the Veterans Health Administration who were treated with thyroid hormone replacement for hypothyroidism from 2004 to 2017.

Treatment included either thyroxine (T4) alone or T4 plus liothyronine (T3) combination, and patients with at least two outpatient TSH measurements were included. Those with thyroid cancer or on medications affecting thyroid function, such as amiodarone, were excluded.

At least one TSH measurement falling below 0.5 mIU/L, indicating over-replacement, occurred in 31.3% (236,930) of patients, which is consistent with rates of over-replacement reported in previous studies.

With a median follow-up of 59 months, atrial fibrillation occurred in 67,772 (10.5%) patients.

Specifically, for a TSH level below 0.1 mIU/L, the odds ratio (OR) for atrial fibrillation was 1.16 (95% CI, 1.10 - 1.22) compared with normal (euthyroid) TSH ranges (0.5-5.5 mIU/L).

However, there was no increased risk of atrial fibrillation for levels between 0.1-0.5 mIU/L (OR, 0.94).

Researchers were also surprised to find a higher risk of atrial fibrillation in those with TSH levels > 5.5 mIU/L (indicating under treatment) (OR, 1.18; 95% CI, 1.52 - 1.21).

Looking at incident cerebrovascular accidents (CVAs), such as ischemic and thrombotic/embolic stroke, among 692,537 patients in the Veteran Affairs cohort, there were 16,878 (2.4%) incident CVAs.

For TSH levels < 0.1 mIU/L, the OR for CVA was 1.16 (95% CI, 1.05 - 1.28) and for TSH levels 0.1-0.5 mIU/L, the OR was 1.11 (95% CI, 1.04 - 1.14), both compared with euthyroid patients.

Again, undertreatment was also associated with higher risk: patients with TSH levels ≥ 5.5 mIU/L had an OR for CVAs of 1.33 (95% CI, 1.27 - 1.39) compared with those with normal TSH levels.

"We are still thinking about how to interpret the unexpected results in those undertreated, as mechanisms remain unclear," Papaleontiou said.

As would be expected, risk factors such as older age and hypertension were associated with atrial fibrillation and, in particular, a prior history of atrial fibrillation was significantly associated with risk for CVA (OR, 1.55).

Lower TSH Level Independently Associated With AF and CVA

The fact that lower TSH was independently associated with the outcomes is particularly important in light of the fact that, in these cases, lower TSH can be seen as a modifiable risk factor, Papaleontiou said.

"The most surprising finding of our study is that low TSH was independently associated with incident stroke in thyroid hormone users, even when controlling for prior history of atrial fibrillation, which is the most common mechanism thought to lead to stroke in hyperthyroidism," she noted.

"This suggests that there may be additional mechanisms leading to increased risk of stroke in patients who are over-replaced with thyroid hormone, and a low TSH is a modifiable factor," Papaleontiou said.

89th Annual Meeting of the American Thyroid Association. Abstract #12. Presented October 31, 2019.

Written by
Timsywhimsy profile image
Timsywhimsy
To view profiles and participate in discussions please or .
Read more about...
13 Replies
SlowDragon profile image
SlowDragonAdministrator

As they didn’t measure Ft4 or Ft3.....the whole test seems flawed

Low TSH with high Ft4 and low Ft3....typical on levothyroxine mono therapy is completely different to low TSH on combination treatment of Levo plus T3

At least they noted that high TSH also linked to atrial fibrillation

Other research

academic.oup.com/jcem/artic...

In summary, patients on long-term T4 with either an increased serum TSH (>4 mU/liter) or a suppressed TSH (<0.03 mU/liter) have an increased risk of cardiovascular disease, dysrhythmias, and fractures when compared with patients with a TSH within the laboratory reference range. Patients with a low, but not suppressed, TSH (0.04–0.4 mU/liter) had no increased risk of these outcomes in this study.

Low dose T3 for heart patients

laboratoryequipment.com/new...

SlowDragon profile image
SlowDragonAdministrator

Also this research by Prof A Toft

heart.bmj.com/content/84/4/...

Over replacement with thyroxine?

There is some concern that administering thyroxine in a dose which suppresses serum TSH may provoke significant cardiovascular problems, including abnormal ventricular diastolic relaxation, a reduced exercise capacity, an increase in mean basal heart rate, and atrial premature contractions.12 Apart from an increase in left ventricular mass index within the normal range, these observations have not been verified.13 Moreover, there is no evidence, despite the findings of the Framingham study, that a suppressed serum TSH concentration in a patient taking thyroxine in whom serum T3 is unequivocally normal is a risk factor for atrial fibrillation.

in reply toSlowDragon

It’s helpful to bear in mind that this piece is 20 years old and therefore will not refer to research published after that.

cazmania7 profile image
cazmania7

It’s all a worry and a bit scary this. I don’t really know what AF is but know it’s to do with the heart. My heart rate seems to be more active and irregular since adding to T3 to my T4 and lowering my TSH but quite frankly I’m desperate so will ride these sensations out in the hope of recovery like so many on this forum. On this occasion I’m going to listen to those with direct personal experience.

And to be honest I don’t care if I die early from stroke of my quality of life is improved. It’s been a bit crap for several years lol.

It’s good to see both sides though and I’ll save this thread for when my Drs eventually notice that I’m up to something when I have a blood test hehe!

This is a summary of research findings/gaps in research etc:

liebertpub.com/doi/10.1089/...

Clinical studies of arrhythmias

Clinically, patients with thyroid hormone excess have an increased risk of atrial fibrillation. The threshold of thyroid function at which that risk becomes clinically significant has been the subject of analyses of observational studies. In participants ≥60 years of age and older enrolled in the Framingham Heart Study, TSH ≤0.1 mIU/L was associated with a 3.3-fold increase in atrial fibrillation risk (53). A subsequent analysis of the Cardiovascular Health Study showed that there was a 2-fold increased risk of atrial fibrillation in individuals ≥65 years of age with a low TSH concentration (<0.45 mIU/L), even when free T4 concentrations were normal (subclinical hyperthyroidism) (54). There was a 1.85-fold increase in risk, even in those with TSH concentrations of 0.1–0.44 mIU/L. These findings have been confirmed in an individual patient data meta-analysis from the Thyroid Studies Collaboration (22).

Additional analyses have explored whether there is a gradient of risk for developing atrial fibrillation, even within the normal reference range of thyroid function tests. Data show increasing risk with decreasing TSH within the normal reference range in the Rotterdam Study (55) and with increasing free T4 within the reference range but not with concentrations of TSH or total T3 within their respective reference ranges in the Cardiovascular Health Study (56). This gradient of risk within the reference range was clinically significant in the older population (≥65 years of age) enrolled in the Cardiovascular Health Study, with an absolute risk difference of 11 per 1000 person years between the lowest and highest quartiles of free T4 (56). The association between free T4 within the reference range and atrial fibrillation was recently confirmed in a meta-analysis in the Thyroid Studies Collaboration (18).

The relative effects of using different thyroid hormone preparations—levothyroxine, L-triiodothyronine, and combinations of the two hormones (as with desiccated thyroid or synthetic combinations)—on arrhythmia risk have not been well characterized. Both endogenous T4 and levothyroxine have a 7-day half-life, whereas T3 and L-triiodothyronine have a 1-day half-life. T4 is converted to T3 through deiodination. However, levels of T4 and T3 differ between levothyroxine users and individuals in the euthyroid state at similar levels of TSH. Individuals with normal TSH levels who are taking levothyroxine therapy have higher serum free T4 concentrations while taking levothyroxine than when they were in the euthyroid state before a thyroidectomy (57) or compared with individuals in the euthyroid state not taking levothyroxine (58). In addition, levothyroxine users with exogenous subclinical hyperthyroidism have lower T3 levels than their nonuser counterparts with endogenous subclinical hyperthyroidism. These differences suggest that the risks derived from studies of endogenous subclinical hyperthyroidism may not apply to individuals with exogenous subclinical hyperthyroidism. Scottish registry data support an increased risk of arrhythmia in patients taking levothyroxine who have a TSH level ≤0.03 mIU/L, but no increase in risk when TSH lies between 0.04 and 0.4 mIU/L (59), although free T4 and T3 levels were not available in this study. There is concern that exogenous T3 taken in excessive amounts can precipitate arrhythmias, but the threshold at which this risk is increased, and the effects of single versus multiple daily doses, is not known.

Beyond its effects on the genesis of atrial arrhythmias, thyroid hormone can have a paradoxical effect on ventricular repolarization, as reflected in the corrected QT (QTc) interval. Hyperthyroidism has been associated with both QTc prolongation (60) and short QTc intervals (61), and hypothyroidism with QTc prolongation and a heightened risk for torsades de pointes (62). These observations may be attributed to the net effect in context of sympathetic tone, genetic and other medical characteristics of the patient, which determines whether and how a hypothyroid or hyperthyroid state might provoke either bradyarrhythmias or tachyarrhythmias. Thyroid hormonal imbalances, particularly hyperthyroidism, can also exaggerate the effects of catecholamines, enhancing the risk of arrhythmogenesis (63).

SlowDragon profile image
SlowDragonAdministrator in reply to

Exactly.....On levothyroxine monotherapy

"Individuals with normal TSH levels who are taking levothyroxine therapy have higher serum free T4 concentrations while taking levothyroxine than when they were in the euthyroid state before a thyroidectomy (57) or compared with individuals in the euthyroid state not taking levothyroxine (58). "

In order to try to increase low Ft3 on just levothyroxine many many patients find it's frequently necessary to have higher FT4, sometimes above top of range .........

The better alternative is to add small dose of T3 alongside

in reply toSlowDragon

I have read it....was just pointing out it’s not the most up to date paper

humanbean profile image
humanbean

Can you give us the link to the article you've posted please. I always like to read any comments by medical professionals on Medscape.

Timsywhimsy profile image
Timsywhimsy

medscape.com/viewarticle/92...

Here’s the link. If it doesn’t work try googling the title of the study.

I’m not trying to be alarmist and I do understand that some people say they need tsh suppressed to feel well. I just don’t want anyone to be cavalier about it. I had my tsh suppressed for about a year on combination therapy. I didn’t feel any better than with it merely low. Perhaps my frees were still not ideal, I don’t really know. But with information like the above study it’s a bit scarier to just keep upping doses hoping to feel well.

My tsh was 1.2 at the time but this past summer I developed SVT, which is a type of arrhythmia. I was in the ambulance and at the hospital many times and ended up with a cardiac ablation. It was terrifying. About a month ago I started upping my meds again (still don’t think tsh was suppressed) and got another quick arrhythmia.

I don’t know if the thyroid meds had anything to do with it, but it gives me pause. And then I saw this latest study. Until someone has had an arrhythmia they don’t know how scary and life altering it can be. Pop on over to the Afib group if you want an idea.

Personally, I don’t think I’ll ever again feel comfortable suppressing tsh. And I don’t subscribe to the advice of testing first thing so we can fool our doctors about where out tsh truly lies. We should all have an accurate picture of what’s going on in our bodies—then, of course, we can choose which risks to take.

london81 profile image
london81 in reply toTimsywhimsy

i agree with caution, and not playing about with our hearts. I was in the hospital with my mum watching her being tested for stroke and it was terrifying. I had chest pains on NDT and t3 and adjusted down immediately. However, the consultant endo I saw said TSH is always supressed on NDT/t3, so what is the alternative?

Timsywhimsy profile image
Timsywhimsy in reply tolondon81

I see people saying this a lot—that tsh is always suppressed on ndt/t3. I don’t think this is necessarily true. I’ve taken ndt and t3 and my tsh is higher or lower depending on my dose, not just the fact that I’m taking it. Tsh swings more when I take t3 or ndt. I suspect this is a reason docs don’t like using it—it makes it hard to know what your tsh is. When you take t4 only tsh stays stable through the day, whereas tsh falls after t3 dose but is back to ‘normal’ after 24 hours or so. At least that’s how it’s been for me.

The study I linked did specifically say that it was looking at patients on ALL forms of replacement, not just t4.

Again, not trying to ruffle any feathers, I just want us all making our decisions on whatever facts we can scrounge together.

london81 profile image
london81 in reply toTimsywhimsy

oh yes definitely good to discuss and share ideas too! thanks for the information :)

humanbean profile image
humanbean

I liked this comment from one of the replies to the article :

Dr. Andrew Johnstone| Family Medicine

Nov 11, 2019

So.....a patient comes in who has a great diet, structured exercise, yet is gaining weight and is profoundly fatigued even if she gets plenty of rest. No other endocrine issues, including insulin resistance, to account for the symptoms. Her resting heart rate is 68, her ankle and knee reflexes are barely existent and sluggish, she has pretibial edema, thinning hair, and no lateral brows. Her free T3 is 3.1, free T4 is 2.8, and reverse T3 is 28.

Yet because her TSH is 0.02, I am to conclude she is "hyperthyroid"....?

This defies logic, common sense, and basic physiology.

If the patient was seeing a doctor in the UK the answer to the commenter's final question is "Yes", because UK treatment only really caters for the TSH. Central hypothyroidism has effectively been "invisibled" - it simply isn't considered to be real any more in the minds of some doctors.

Not what you're looking for?

You may also like...

Apparently only elevated TSH gives significantly greater risk of OP, AF, heart disease and mortality.

Another useful downloadable paper with some very interesting graphs. As we thought, lower TSH...
diogenes profile image
Remembering

Atrial Fibrillation, Hypothyroidism and T4

How interesting to see a paper which suggests that thyroid hormone might have a very positive role...
helvella profile image
Administrator

Thyroid hormone treatment intensity linked to increased risk of cardiovascular mortality

Just how long can this go on? Positively defining in terms of TSH alone. "… exogenous...
helvella profile image
Administrator

Suboptimal Thyroid Hormone Replacement is Associated with Worse Hospital Outcomes

Not saying this paper doesn't have its place. Of course it does, otherwise there is too much...
helvella profile image
Administrator

useful 'Evidence' that TSH between 0.04 - 0.4 has no increased risk to patients on Levothyroxine (UPDATED~new study does show small risk)

This paper forms part of the evidence base for the current NHS thyroid treatment guidelines , it...
tattybogle profile image